Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (…
In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
Alzheimer’s disease is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing the deterioration of patients’ social and…
Epi Data Slicer – Alzheimer's Disease